[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488110":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":42,"responsibleParty":44,"collaborators":47,"id":50,"slug":42,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":42,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":75,"whyStopped":42,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":42},{"fullName":5,"class":6},"Simon Fraser University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Glyceryl trinitrate sublingual spray","EXPERIMENTAL","Glyceryl trinitrate (GTN) sublingual spray will be administered up to three times every fifteen minutes, each dose being 0.4mg.",[13],"Drug: Glyceryl Trinitrate Only Product in Oromucosal Dose Form",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo sublingual spray","PLACEBO_COMPARATOR","An approximate flavour-matched placebo sublingual spray will be administered up to three times every fifteen minutes.",[19],"Other: Placebo sublingual spray",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Glyceryl Trinitrate Only Product in Oromucosal Dose Form","Glyceryl trinitrate will be administered via sublingual spray.",[9],[27],"GTN",{"type":6,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"A placebo sublingual spray will be administered.",[15],[32],"Placebo spray",[34],{"name":35,"affiliation":5,"role":36},"Victoria Claydon, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Victoria Claydon, Dr.","CONTACT","778-782-8513",null,"victoria_claydon@sfu.ca",{"type":36,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Dr. Victoria Claydon","Professor, Principal Investigator",[48],{"name":49,"class":6},"University of British Columbia","100488110",false,"NCT05635851","NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI","NO AD","Inclusion Criteria:\n\n* participants must have had a traumatic spinal cord injury at least one year ago\n* regular bowel care routine\n* can communicate in English\n\nExclusion Criteria:\n\n* cauda equina or conus lesions\n* currently use ventilator\n* colostomy, or do not perform regular bowel care\n* skin breakdown (pressure sores)\n* cannot communicate in English\n* under 19 years old\n* possibly or certainly pregnant\n* medical\u002Fpsychiatric condition or substance abuse that is likely to affect ability to complete study\n* currently using medications containing PDE-5 inhibitors\n* currently using medications containing GTN\n* allergy to GTN","ALL","19 Years","80 Years",{"count":60,"type":61},26,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This project aims to evaluate the safety and efficacy of using a short-acting drug to reduce the maximal blood pressure during dangerous blood pressure spikes that happen during bowel care in individuals with spinal cord injury. the investigators will monitor the physiological effects of this drug during at-home bowel care to best understand the drug's effects in typical use.",[67,68],"Spinal Cord Injuries","Autonomic Dysreflexia",[70,71,72,73,74],"spinal cord injury","autonomic dysreflexia","blood pressure","bowel care management","defecation","NOT_YET_RECRUITING","2026-04-22",{"date":78,"type":79},"2026-04-23","ACTUAL",{"date":81,"type":61},"2026-12",{"date":83,"type":61},"2028-02",{"name":5,"class":6}]